High affinity mage-a1-specific tcrs and uses thereof

Abstract

The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human MAGE-A1 epitopes), T cells expressing such high affinity antigen-specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress one or more of these antigens, such as in cancer.

1 .- 99 . (canceled) 
     
     
         100 . An isolated modified cell comprising a heterologous polynucleotide encoding a binding protein, wherein the encoded binding protein comprises:
 (a) a T cell receptor (TCR) α-chain variable (V α ) domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively, and a TCR β-chain variable (V β ) domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively;   (b) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:30-32, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:27-29, respectively;   (c) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:36-38, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:33-35, respectively;   (d) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:42-44, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:39-41, respectively; or   (e) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:24-26, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:21-23, respectively.   
     
     
         101 . The isolated modified cell of  claim 100 , wherein the binding protein is a T cell receptor (TCR) comprising a TCRα polypeptide chain and a TCRβ polypeptide chain. 
     
     
         102 . The isolated modified cell of  claim 100 , wherein the binding protein is capable of binding to a MAGE-A1 peptide:human leukocyte antigen (HLA)-A*0201 complex on a cell surface. 
     
     
         103 . The isolated modified cell of  claim 100 , wherein the encoded binding protein of (a) is capable of specifically binding to a MAGE-A1 peptide:HLA-A*201 complex with a K d  less than or equal to about 10 −8  M. 
     
     
         104 . The isolated modified cell of  claim 100 , wherein the V β  domain of the encoded binding protein is derived from a TRBV30 allele, a TRBV29 allele, or a TRBV9 allele. 
     
     
         105 . The isolated modified cell of  claim 100 , wherein the V α  domain of the encoded binding protein is derived from a TRAV38-1 allele, a TRAV34 allele, a TRAV16 allele, or a TRAV5 allele. 
     
     
         106 . An isolated modified cell comprising a heterologous polynucleotide encoding a binding protein, wherein the encoded binding protein comprises:
 (a) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively;   (b) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:30-32, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:27-29, respectively;   (c) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:36-38, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:33-35, respectively;   (d) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:42-44, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:39-41, respectively; or   (e) a TCR V α  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:24-26, respectively, and a TCR V β  domain having CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:21-23, respectively; and   wherein:   (i) the encoded V α  domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOS.:3, 7, 11, 15, and 19; and   (ii) the encoded V β  domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID NOS.:1, 5, 9, 13, and 17.   
     
     
         107 . The isolated modified cell of  claim 106 , wherein the binding protein is capable of specifically binding to a MAGE-A1 peptide:human leukocyte antigen (HLA)-A*0201 complex on a cell surface. 
     
     
         108 . The isolated modified cell of  claim 100 , wherein the encoded binding protein comprises V α  CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively, and V β  CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively. 
     
     
         109 . The isolated modified cell of  claim 100 , wherein the encoded binding protein is a pre-binding protein and wherein the encoded V α  domain comprises or consists of the amino acid sequence of SEQ ID NO.:3, 7, 11, 15, or 19. 
     
     
         110 . The isolated modified cell of  claim 100 , wherein the encoded binding protein is a pre-binding protein and wherein the encoded V β  domain comprises or consists of the amino acid sequence of SEQ ID NO.:1, 5, 9, 13, or 17. 
     
     
         111 . The isolated modified cell of  claim 100 , further comprising a heterologous polynucleotide encoding a TCR α-chain constant (C α ) domain and/or a heterologous polynucleotide encoding a TCR β-chain constant (C β ) domain. 
     
     
         112 . The isolated modified cell of  claim 111 , wherein: the TCR C α  domain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO.:4, 8, 12, 16, or 20; and/or the TCR C β  domain comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO.:2, 6, 10, 14, or 18. 
     
     
         113 . The isolated modified cell of  claim 100 , wherein the encoded binding protein is a pre-binding protein and the modified cell comprises:
 (i) a polynucleotide encoding (1) a TCR α-chain pre-protein comprising (1)(a) a V α  domain comprising or consisting of SEQ ID NO.: 19 and (1)(b) a C α  domain comprising or consisting of SEQ ID NO.: 20, and a polynucleotide encoding (2) a TCR β-chain pre-protein comprising (2)(a) a V β  domain comprising or consisting of SEQ ID NO.: 17 and (2)(b) a C β  domain comprising or consisting of SEQ ID NO.: 18;   (ii) a polynucleotide encoding (1) a TCR α-chain pre-protein comprising (1)(a) a V α  domain comprising or consisting of SEQ ID NO.: 7 and (1)(b) a C α  domain comprising or consisting of SEQ ID NO.: 8, and a polynucleotide encoding (2) a TCR β-chain pre-protein comprising (2)(a) a V β  domain comprising or consisting of SEQ ID NO.: 5 and (2)(b) a C β  comprising or consisting of SEQ ID NO.: 6;   (iii) a polynucleotide encoding (1) a TCR α-chain pre-protein comprising (1)(a) a V α  domain comprising or consisting of SEQ ID NO.: 11 and (1)(b) a C α  domain comprising or consisting of SEQ ID NO.: 12, and a polynucleotide encoding (2) a TCR β-chain pre-protein comprising (2)(a) a V β  domain comprising or consisting of SEQ ID NO.: 9 and (2)(b) a C β  domain comprising or consisting of SEQ ID NO.: 10;   (iv) a polynucleotide encoding (1) a TCR α-chain pre-protein comprising (1)(a) a V α  domain comprising or consisting of SEQ ID NO.: 15 and (1)(b) a C α  comprising or consisting of SEQ ID NO.: 16, and a polynucleotide encoding (2) a TCR β-chain pre-protein comprising (2a) a V β  domain comprising or consisting of SEQ ID NO.: 13 and (2)(b) a C β  domain comprising or consisting of SEQ ID NO.: 14; or   (v) a polynucleotide encoding (1) a TCR α-chain pre-protein comprising (1)(a) a V α  domain comprising or consisting of SEQ ID NO.: 3 and (1)(b) a C α  domain comprising or consisting of SEQ ID NO.: 4, and a polynucleotide encoding (2) a TCR β-chain pre-protein comprising (2)(a) a V β  domain comprising or consisting of SEQ ID NO.: 1 and (2)(b) a C β  domain comprising or consisting of SEQ ID NO.: 2.   
     
     
         114 . The isolated modified cell of  claim 100 , wherein the modified cell is an immune cell selected from a T cell, a NK cell, or a NK-T cell. 
     
     
         115 . The isolated modified cell of  claim 114 , wherein the immune cell is a CD4+ T cell, a CD8+ T cell, or both. 
     
     
         116 . The isolated modified cell of  claim 115 , wherein the modified cell is a CD4+ T cell and further comprises a heterologous polynucleotide encoding at least an extracellular portion of a CD8 co-receptor. 
     
     
         117 . The isolated modified cell of  claim 116 , wherein the encoded at least an extracellular portion of a CD8 co-receptor comprises:
 (i) the CD8 co-receptor α-chain amino acid sequence of SEQ ID NO.:143; and   (ii) the CD8 co-receptor β-chain amino acid sequence of any one of SEQ ID NOs.:144-145.   
     
     
         118 . The isolated modified cell of  claim 114 , wherein the immune cell is a human immune system cell. 
     
     
         119 . A composition comprising a plurality of modified cells according to  claim 100  and a pharmaceutically acceptable carrier, diluent, or excipient. 
     
     
         120 . The composition of  claim 119 , wherein the plurality of cells comprises CD4+ T cells, CD8+ T cells, or both. 
     
     
         121 . An isolated polynucleotide encoding a binding protein having a TCR V α  domain and a TCR V β  domain, wherein:
 (i) (a) the encoded V α  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively, and the encoded V β  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively;
 (b) the encoded V α  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:30-32, respectively, and the encoded V β  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:27-29, respectively; 
 (c) the encoded V α  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:36-38, respectively, and the encoded V β  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:33-35, respectively; 
 (d) the encoded V α  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:42-44, respectively, and the encoded V β  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:39-41, respectively; or 
 (e) the encoded V α  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:24-26, respectively, and the encoded V β  domain comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:21-23, respectively; and 
 
 (ii) the V α -encoding polynucleotide comprises a nucleotide sequence having at least 80% identity to SEQ ID NO.:58, 66, 74, 82, or 90, and the V β -encoding polynucleotide comprises a nucleotide sequence having at least 80% identity to SEQ ID NO.:56, 64, 72, 80, or 88. 
 
     
     
         122 . The isolated polynucleotide of  claim 121 , wherein the encoded binding protein comprises V α  CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively, and V β  CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively. 
     
     
         123 . The isolated polynucleotide of  claim 122 , wherein the encoded binding protein is a pre-binding protein, wherein the encoded V α  domain comprises or consists of the amino acid sequence of SEQ ID NO.: 19 and the encoded V β  domain comprises or consists of the amino acid sequence of SEQ ID NO.: 17. 
     
     
         124 . The isolated polynucleotide of  claim 121 , wherein the V α -encoding polynucleotide comprises or consists of a nucleotide sequence having at least 80% identity to SEQ ID NO.:90, and the V β -encoding polynucleotide comprises a nucleotide sequence having at least 80% identity to SEQ ID NO.:88. 
     
     
         125 . An isolated expression vector, comprising a polynucleotide according to  claim 121  operably linked to an expression control sequence. 
     
     
         126 . A method for treating a hyperproliferative disorder associated with MAGE-A1 expression, comprising administering to a human subject in need thereof a modified cell according to  claim 100 . 
     
     
         127 . The method of  claim 126 , wherein the human subject is further receiving an anti-PD-1 antibody or an anti-PD-L1 antibody. 
     
     
         128 . The method according to  claim 126 , wherein the modified cell is an immune cell selected from a T cell, a NK cell, or a NK-T cell. 
     
     
         129 . The method according to  claim 126 , wherein the hyperproliferative disorder is a hematological malignancy or a solid cancer. 
     
     
         130 . The method according to  claim 129 , wherein the hematological malignancy is selected from acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), chronic eosinophilic leukemia (CEL), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or multiple myeloma (MM). 
     
     
         131 . The method according to  claim 129 , wherein the solid cancer is selected from non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer, malignant melanoma, colon cancer, colorectal adenocarcinoma, colorectal cancer, biliary cancer, bladder cancer, bone and soft tissue carcinoma, brain tumor, breast cancer, cervical cancer, desmoid tumor, embryonal cancer, endometrial cancer, esophageal cancer, gastric cancer, gastric adenocarcinoma, glioblastoma multiforme, gynecological tumor, head and neck squamous cell carcinoma, hepatic cancer, lung cancer, mesothelioma, osteosarcoma, pancreatic cancer, pancreatic ductal adenocarcinoma, primary astrocytic tumor, primary thyroid cancer, prostate cancer, renal cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, soft tissue sarcoma, testicular germ-cell tumor, urothelial cancer, uterine sarcoma, or uterine cancer. 
     
     
         132 . The method according to  claim 126 , wherein the immune cell is a human immune system cell. 
     
     
         133 . An isolated modified T cell comprising a heterologous polynucleotide encoding a binding protein, wherein the encoded binding protein comprises:
 (i) a T cell receptor (TCR) α-chain variable (Vα) domain comprising CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively; and   (ii) a TCR β chain variable (Vβ) domain comprising CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively,   wherein the T cell is a CD4 +  T cell or a CD8 +  T cell.   
     
     
         134 . The isolated modified T cell of  claim 133 , wherein:
 (a) the V α  domain comprises or consists of the amino acid sequence of SEQ ID NO.: 19, and the V α  domain is comprised in a TCR α-chain pre-protein that further comprises a C α  domain comprising or consisting of the amino acid sequence of SEQ ID NO.: 20; and   (b) the V β  domain comprises or consists of the amino acid sequence of SEQ ID NO.: 17, and the V β  domain is comprised in a TCR β-chain pre-protein that further comprises a C β  domain comprising or consisting of the amino acid sequence of SEQ ID NO.: 18.   
     
     
         135 . An isolated modified T cell comprising a heterologous polynucleotide encoding a binding protein, wherein the encoded binding protein comprises:
 (i) a T cell receptor (TCR) α-chain variable (Vα) domain comprising CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:48-50, respectively; and   (ii) a TCR β chain variable (Vβ) domain comprising CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOS.:45-47, respectively,   wherein the T cell is a CD4 +  T cell and further comprises a heterologous polynucleotide encoding at least an extracellular portion of a CD8 co-receptor.